Keywords: USA, FDA, Novartis, Roche, Biogen, Rituxan, QAB149, indacaterol, Approval delay
US FDA “Complete Response” letters delay Novartis and Roche/Biogen products
Article | 19 October 2009
Swiss drug majors Novartis and Roche, the latter in conjunction with its partner Biogen Idec and US subsidiary Genentech, have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
